ANALYST VIEW - Erste raises target price for Hungary's Richter

Recommendation remains 'Accumulate'

Hungary Richter transfers shares to employee share programme

Almsot half a million shares

Hungary fund managers focus on Mol in December

Annual BUX forecasts now more pessimistic

Richter employees may now sell their shares

Lock-up period expires

Richter keeps buying treasury shares

Stock of own shares nears 1 mn

Hungary Richter gets good news from Japan

Richter product launched in Japan by partner

Hungary's BUX index hits all-time high on Monday

OTP also sets new record price

Hungary BUX index hits all-time high

Mol, OTP ride the bull

Hungarian fund managers have new top pick in October

Richter was the flavour of the month

Hungarys' Richter revises 2019 estimates higher

Management turn more upbeat

Hungary Richter Q3 sales, profit driven by Vraylar sales

Revenue rose 28.2% y/y

Hungary Richter seen reporting record quarterly revenue

Profit expected to jump from low base

Hungary's Richter expects cariprazine to drive growth

Not just in the U.S. but in Europe as well

Hungary's Richter signs license and development agreement with Mycovia

For RVVC drug VT-1161

Richter announces approval in Japan of its licensed-out biosimilar teriparatide

BlackRock stake in Hungary's Richter below 5%

U.S. company informs Richter about decrease on Monday.

Hungary Richter wonderdrug to be distributed in Asia

Mitsubishi Tanabe will distribute cariprazine in Thailand and Singapore.

Hungarian drugmaker Richter projects slight growth in sales this year

With a 10% decrease in Russia and 20% in China

Vraylar sales in U.S. boost Richter Q2 result

Revenue rose 8.5% to HUF 120 billion.

Richter expected to post higher revenue, lower profit in Q2

Analysts forecast 30% lower net profit.